Publications & Posters
Scholary publications
Spinal Muscular Atrophy
Apitegromab
July 2024
Frontiers in Neurology
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
Fibrosis
SRK-373
July 2024
Science Signaling
An antibody that inhibits TGFβ1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis
Spinal Muscular Atrophy
Apitegromab
February 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Spinal Muscular Atrophy
Apitegromab
July 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
Spinal Muscular Atrophy
Apitegromab
May 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Immuno-Oncology
SRK-181
March 2021
International Journal of Toxicology
